Natixis Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.21M | Buy |
29,928
+3,199
| +12% | +$701K | 0.01% | 824 |
|
|
2026
Q1 | $5.05M | Buy |
26,729
+1,734
| +7% | +$303K | 0.01% | 843 |
|
|
2025
Q4 | $4.25M | Sell |
24,995
-1,554
| -6% | -$238K | 0.01% | 860 |
|
|
2025
Q3 | $3.5M | Buy |
26,549
+5,342
| +25% | +$641K | 0.01% | 942 |
|
|
2025
Q2 | $2.25M | Sell |
21,207
-2,597
| -11% | -$282K | ﹤0.01% | 1052 |
|
|
2025
Q1 | $2.96M | Buy |
23,804
+5,259
| +28% | +$686K | 0.01% | 951 |
|
|
2024
Q4 | $2.28M | Sell |
18,545
-4,289
| -19% | -$506K | ﹤0.01% | 1056 |
|
|
2024
Q3 | $2.54M | Buy |
22,834
+1,603
| +8% | +$176K | 0.01% | 1015 |
|
|
2024
Q2 | $2.27M | Buy |
21,231
+2,054
| +11% | +$226K | ﹤0.01% | 1007 |
|
|
2024
Q1 | $2.31M | Buy |
19,177
+3,752
| +24% | +$460K | 0.01% | 996 |
|
|
2023
Q4 | $1.9M | Sell |
15,425
-12,690
| -45% | -$1.58M | 0.01% | 1021 |
|
|
2023
Q3 | $3.64M | Buy |
28,115
+11,176
| +66% | +$1.49M | 0.01% | 806 |
|
|
2023
Q2 | $2.1M | Sell |
16,939
-2,082
| -11% | -$280K | 0.01% | 948 |
|
|
2023
Q1 | $2.78M | Sell |
19,021
-1,650
| -8% | -$244K | 0.01% | 856 |
|
|
2022
Q4 | $3.29M | Buy |
20,671
+2,103
| +11% | +$308K | 0.01% | 795 |
|
|
2022
Q3 | $2.48M | Sell |
18,568
-8,295
| -31% | -$1.26M | 0.01% | 838 |
|
|
2022
Q2 | $4.19M | Buy |
26,863
+719
| +3% | +$111K | 0.02% | 700 |
|
|
2022
Q1 | $4.07M | Buy |
26,144
+6,026
| +30% | +$874K | 0.02% | 745 |
|
|
2021
Q4 | $2.56M | Sell |
20,118
-146
| -0.7% | -$19.2K | 0.01% | 882 |
|
|
2021
Q3 | $2.64M | Buy |
20,264
+2,007
| +11% | +$303K | 0.01% | 846 |
|
|
2021
Q2 | $3.24M | Buy |
18,257
+134
| +0.7% | +$23.2K | 0.02% | 761 |
|
|
2021
Q1 | $2.98M | Sell |
18,123
-212
| -1% | -$34.9K | 0.02% | 759 |
|
|
2020
Q4 | $3.03M | Sell |
18,335
-15,222
| -45% | -$2.27M | 0.02% | 723 |
|
|
2020
Q3 | $4.79M | Buy |
33,557
+5,031
| +18% | +$624K | 0.03% | 532 |
|
|
2020
Q2 | $3.15M | Sell |
28,526
-16,604
| -37% | -$1.84M | 0.02% | 659 |
|
|
2020
Q1 | $4.5M | Buy |
45,130
+1,890
| +4% | +$244K | 0.04% | 483 |
|
|
2019
Q4 | $6.46M | Buy |
43,240
+2,699
| +7% | +$367K | 0.05% | 441 |
|
|
2019
Q3 | $5.2M | Buy |
40,541
+1,449
| +4% | +$194K | 0.04% | 464 |
|
|
2019
Q2 | $5.57M | Buy |
39,092
+9,354
| +31% | +$1.26M | 0.05% | 426 |
|
|
2019
Q1 | $4.25M | Buy |
+29,738
| New | +$3.88M | 0.04% | 498 |
|
|
2014
Q3 | – | Sell |
-5,347
| Closed | -$786K | – | 1128 |
|
|
2014
Q2 | $786K | Sell |
5,347
-252
| -5% | -$34.9K | 0.01% | 880 |
|
|
2014
Q1 | $776K | Sell |
5,599
-5,110
| -48% | -$769K | 0.01% | 836 |
|
|
2013
Q4 | $1.35M | Sell |
10,709
-1,248
| -10% | -$129K | 0.02% | 667 |
|
|
2013
Q3 | $1.1M | Sell |
11,957
-2,114
| -15% | -$171K | 0.02% | 659 |
|
|
2013
Q2 | $967K | Buy |
+14,071
| New | +$860K | 0.02% | 676 |
|
Other funds holding JAZZ
Natixis Advisors's JAZZ Position: Q2 2026 in Review
Natixis Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 12% in Q2 2026, buying an estimated $701K and bringing the position to 29,928 shares worth $7.21M. The position accounts for 0.01% of the portfolio, ranked #824.
Natixis Advisors first reported a position in JAZZ in Q2 2013 and has held it in 35 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Natixis Advisors held 29,928 shares of Jazz Pharmaceuticals worth $7.21M as of Q2 2026.
- Natixis Advisors bought 3,199 Jazz Pharmaceuticals shares in Q2 2026, an estimated $701K.
- Jazz Pharmaceuticals made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #824 holding.
- Natixis Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.